Clinical Trials for Non-Small Cell Lung Cancer
13 Open Trials
| Trial Type | Protocol No. & Open Date | Summary |
|---|---|---|
| Therapeutic | VICCTHN1307 06/06/2013 | A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations |
| Therapeutic | VICCTHN1242 10/24/2012 | A Phase IB, Multi-Center,Open-Label Study of the MTOR Kinase Inhibitor CC-223 in Combination with Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer |
| Therapeutic | VICCTHN1123 07/27/2012 | A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects with Advanced Non-Small Cell Lung Cancer and BRAF. Mutations |
| Therapeutic | VICCTHO1042 10/11/2011 | A Phase 1-2 Trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer |
| Therapeutic | VICCTHO1079 07/27/2011 | Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib versus Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus |
| Therapeutic | ECOGTHNE5508 06/29/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic | ECOGTHO5508-M 02/09/2011 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
| Therapeutic | VICCTHO0730 10/15/2007 | A Phase II Trial of Celecoxib plus Chemotherapy [Docetaxel or Pemetrexed] in Patients with Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer (SPORE) |
| Therapeutic | ECOGTHOE1505 08/30/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC). |
| Therapeutic | ECOGTHOE1505-M 07/27/2007 | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC) |
| Correlative | VICCTHN1164 11/04/2011 | Molecular Profiles for Lung Cancer Pathogenesis and Detection |
| Correlative | VICCTHO0547 12/19/2005 | Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE) |
| Correlative | VICCTHO0136 05/01/2001 | Molecular Fingerprinting of Lung Cancer (SPORE) |
You do not have JavaScript enabled. This site works better with JavaScript turned on.
